TST is the 1^st company in Taiwan entering the plasma fraction market since 1964. We have been demonstrated our sense of urgency and capability in taking strategic actions to address the critical market issue over the past decades.

Plasma products are derived from human plasma and therefore its production is highly dependent on the supply of human plasma, process efficiencies, price and regulatory restrictions. Because of this, some countries consider plasma fraction products as sort of “strategic commodities” and seriously regulates its export and requires to receive special permission from government while there are needs to export to other markets.

Several years ago, globally the market faced critical supply shortage on Immune Globulin and led to a panic in many markets including Taiwan. In order to deal with this critical situation, TST urgently approached Japanese government trying to seek help to import Immune Globulin to Taiwan and very luckily, we finally received Japanese government’s permission and agree to ease this regulation in the name of “global humanitarian rescue”. The outcome of our efforts has saved people’s life who were in needs of this product. We pride ourselves on what we have been done for the market and patients.

There is a total of around 9 players competing in the plasma fraction market where the market size was valued at around US$123 million (2018 quantity of TFDA sealing data @ reimbursement price); and TST led the market with an overall share of 23% in 2018.